Abstractors preferred the clinician-anchored approach as it ... and most practical, method for characterizing tumor-based endpoints from EHR-sourced data. I interviewed at Flatiron Health (New York, NY) in December 2016. As an abstractor you will: Help generate robust data sets by extracting key data points from electronic health records using Flatiron’s proprietary software system Maintain a high level of performance, as measured by passing evaluations and maintaining strong quality and efficiency scores Real-world patterns of molecular testing in advanced melanoma: adherence to guidelines, Overall survival in Non-small cell lung cancer patients with comorbidities treated with frontline chemotherapy or immunotherapy: a real-world data collaboration, Real-world treatment patterns and time on treatment (rwToT) in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) with disease progression on or after platinum-containing chemotherapy in United States (U.S.), Real-world outcomes in patients with locally advanced or metastatic urothelial carcinoma receiving taxane monotherapy following platinum and anti-PD-1/L1 therapy, Assessing real-world biomarker testing rates in metastatic colon cancer, Impact of dose reductions on clinical outcomes among patients (pts) with metastatic pancreatic cancer (mPC) treated with liposomal irinotecan (nal-IRI) in oncology clinics in the United States, Survival outcomes based on sequence of therapy using FOLFIRINOX and nabpaclitaxel + gemcitabine in metastatic pancreatic ductal adenocarcinoma. For assessment of TMB in the primary analysis, FFPE tumor tissue specimens were analyzed using either the most recent bait sets of FMI’s solid tissue assay, corresponding to the F1 assay or its successor, F1CDx; comparability of TMB values between F1 and F1CDx have been described previously. Registered nurse with over 14 years experience in health care. I called in and had a very nice casual/professional interview. Interview. Detailed what your day would look like and resources provided to you. I feel like they should give more realistic medical records. Rates of systemic anticancer therapy (SACT) for advanced non-small cell lung cancer (aNSCLC) in the U.S. 2011-2018. However, as with many jobs at this company and others, the decision makers are essentially looking for a type of personality to give their jobs to -- someone who is easy to manage and has a high tolerance to disorganization. Watch the Abstractor Training Webinars Part 1 and Part 2. Review the Coding Instructions located as a download in the Patient Management Tool (PMT). Are you sure you want to replace it? Learn more about Flatiron's mission, vision and story. I applied online. Assessment of Treatment with Panitumumab, Cetuximab, and Bevacizumab Among mCRC Patients with Wild-Type RAS or BRAF Treated and Community Cancer Centers in the United States → Garawin T, Lowe K, Anthony M, Bohac C What do you anticipate a workday to be like at your home should you be hired with Flatiron? Event agreement, which indicates whether abstractors agreed on the presence or absence of at least one progression event, was 0.94 (95% CI, 0.93 to 0.95). What do you know about breast cancer staging? I interviewed at Flatiron Health (United States). Familiar with all aspects of how cancer is treated, from diagnosis to recovery, and fluent in cancer terminology; Knowledge and experience with AJCC staging 19 Flatiron Health reviews. Copyright © 2008–2021, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. This means we have a chance to impact more lives and deliver better outcomes for patients. They do not pay as much and there is very little status or mobility. Nurse abstractors review patient files to abstract key data. A retrospective analysis based on real-world data, Real-world effectiveness of palbociclib in combination with an aromatase inhibitor as first-line therapy in metastatic breast cancer, Biomarker testing, treatment and survival outcomes in Medicaid compared to commercially insured patients with advanced NSCLC, Value of precision medicine in advanced NSCLC: Real-world outcomes associated with the use of companion diagnostics, Real-world outcomes of advanced melanoma patients treated with pembrolizumab who have failed prior lines of therapy, Impact of antibiotics on overall survival in patients with advanced non-small-cell lung cancer and melanoma treated with first-line immune checkpoint inhibition, Real-world clinical outcomes for advanced/metastatic non-small cell lung cancer patients treated with second line ramucirumab plus docetaxel post frontline platinum based chemotherapy plus immune checkpoint inhibitors, Real-world tumor response to ramucirumab plus docetaxel post platinum-based and immune checkpoint inhibitor therapy in advanced non-small cell lung cancer patients, Carboplatin-based chemotherapy versus immunotherapy in metastatic urothelial carcinoma, Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone plus prednisone/prednisolone: A retrospective study of real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer, Risk factors for progression or death in ovarian cancer patients who completed first-line platinum treatment, Identification and use of treatment options in patients with advanced non-small cell lung cancer after comprehensive genomic profiling: A real-world study, Real-world practice patterns and impact of PD-L1 expression testing in patients with advanced non-small cell lung cancer, Clinical characteristics, treatment patterns, and overall survival in advanced NSCLC patients with and without brain metastases, Validation of broad panel clinical sequencing-based genomic risk stratification in patients with advanced lung adenocarcinomas, The Impact of Delaying ALK Inhibitor Therapy on Outcomes: A Prescription Time Matching Method, Impact of Treatment Sequence on Overall Survival in Metastatic Pancreatic Cancer Patients with Liposomal Irinotecan in the Real-World Setting, Improving the Accuracy of Measuring Duration of Therapy by Identifying Patients Who Remain on Treatment in a Real-World Database, Real World Effectiveness of Nivolumab in Asian Patients in the United States Flatiron Health Database, Medicaid Expansion and Racial Inequities in Next Generation Sequencing Testing in Oncology, Optimization of Natural Language Processing-Supported Comorbidity Classification Algorithms in Electronic Health Records, Machine Learning Model for Cancer Biomarker Identification in Electronic Health Records, Cost-Effectiveness of Multi-Gene Panel Sequencing for Patients with Advanced Melanoma, Treatment characteristics and clinical outcomes in patients with extensive-stage small cell lung cancer treated with carboplatin or cisplatin in combination with etoposide in US clinical practice, Real-world immuno-oncology therapy treatment patterns and outcomes in patients with anaplastic lymphoma kinase positive non-small cell lung cancer in the United States, Treatment characteristics of patients with locally advanced or metastatic non-small cell lung cancer receiving atezolizumab monotherapy in US clinical practice, Development and initial validation of a prognostic score based on structured data from EHRs, Real-world outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥50%) metastatic non-small cell lung cancer (NSCLC), Primary tumor location (PTL) and survival outcomes in a real world cohort of KRAS wild-type (WT) metastatic colorectal cancer (mCRC) patients, Real-world trends in first-line checkpoint inhibitor use in advanced urothelial cell carcinoma, Trends in checkpoint inhibitor therapy for advanced urothelial cell carcinoma at the end of life: Insights from real-world practice, Predictive value of fibroblast growth factor receptor mutations and gene fusions on anti-PD-(L)1 treatment outcomes in patients with advanced urothelial cancer, Treatment patterns and outcomes for metastatic castration-resistant prostate cancer in a real-world setting: A retrospective study of greater than 2500 patients, Treatment characteristics of patients with locally advanced or metastatic urothelial cancer receiving atezolizumab monotherapy in United States clinical practice, Clinical outcome with concurrent or layered treatment with radium-223 and abiraterone: A retrospective study of real-world experience with patients with metastatic castration-resistant prostate cancer, Survival of patients with metastatic HER2 positive gastroesophageal cancer treated with second-line chemotherapy plus trastuzumab or ramucirumab after progression on frontline chemotherapy plus trastuzumab, Comparative effectiveness of nivolumab relative to standard of care for advanced/metastatic gastric or gastroesophageal junction cancer: A simulated treatment comparison, Line of Therapy Definition Impacts Analyses of Second-Line Survival in a Metastatic Pancreatic Cancer Electronic Health Record Database, First-line pembrolizumab monotherapy in metastatic PD-L1 positive non-small cell lung cancer: A real-world analysis of time on treatment in US community oncology practices, Temporally integrated framework for treatment intervals (TIFTI): A framework for extracting drug intervals from longitudinal clinic notes, Influence of Prognostic Factors on Outcomes Among Metastatic Breast Cancer Patients Treated with CDK4&6 Inhibitors in Routine Clinical Practice, Outcomes in patients (pts) with metastatic triple-negative breast cancer (mTNBC) treated in second line (2L) in the US real-world setting, A real world evidence study of BRCA mutations and survival in HER2-negative breast cancer, Time to treatment discontinuation of second-line fulvestrant monotherapy for HR+/HER2− metastatic breast cancer in the real-world setting, Real-world survival of heavily pretreated patients with refractory HR+, HER2- metastatic breast cancer receiving single-agent chemotherapy – A comparison with MONARCH 1, Hepatitis B Testing Rates in Patients with Chronic Lymphocytic Leukemia before and during Administration of Anti-CD20 Therapy, The Real-World Frequency of 24-Hour Urine Protein Electrophoresis (UPEP), Serum Free Light Chain (SFLC), and Serum Protein Electrophoresis (SPEP) Testing in Patients with Multiple Myeloma (MM), Real-World Disparities in Daratumumab Utilization for Patients with Relapsed or Refractory Multiple Myeloma (MM), Dynamic Changes in International Staging System As a Predictor of Survival Outcome in Patients with Advanced Multiple Myeloma, Results of the Pivotal STORM Study (Part 2) in Penta-Refractory Multiple Myeloma (MM): Deep and Durable Responses with Oral Selinexor Plus Low Dose Dexamethasone in Patients with Penta-Refractory MM, Treatment Patterns Among Adults with Newly Diagnosed Primary Immune Thrombocytopenia in the United States, Comparing Bortezomib-Lenalidomide-Dexamethasone (VRd) with Carfilzomib-Lenalidomide-Dexamethasone (KRd) in the Patients with Newly Diagnosed Multiple Myeloma (NDMM) in Two Observational Studies, Real-World Outcomes for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Lenalidomide, Bortezomib, and Dexamethasone, or Bortezomib and Dexamethasone: An Enhanced Electronic Health Records Database Analysis, Treatment Sequencing and Survival Outcomes in BRAF Mutation–Positive Metastatic Melanoma Patients Treated With Immunotherapy in Routine Clinical Practices in the United States, Adjuvant Therapy is Associated with Improved Overall Survival in Advanced Melanoma Patients in the United States, Real-World (RW) Effectiveness of First-Line (1L) Nivolumab (NIVO) Plus Ipilimumab (IPI) or NIVO Monotherapy for Advanced Melanoma (MEL): Subgroup Analysis of a Retrospective Cohort Study, Establishing the Need for Immuno-Oncology (IO) Therapy (tx) in Second-Line (2L) Small Cell Lung Cancer (SCLC), Real-World Dosing Patterns of Patients (Pts) With Metastatic Pancreatic Cancer (MPC) Treated With Liposomal Irinotecan (Nal-iri) in US Oncology Clinics, Assessment of Real-World Effectiveness of First-Line (1L) Nivolumab (NIVO) Plus Ipilimumab (IPI) or NIVO Monotherapy for Advanced Melanoma: A Retrospective Cohort Study, Clinical Outcomes, Treatment Patterns and Health Resource Utilization (HRU) Among Metastatic Breast Cancer (MBC) Patients (pts) with Germline BRCA Mutation (gBRCAm), Comparative Effectiveness of Nab-Paclitaxel vs. Paclitaxel Monotherapy as First-Line (1L) Treatment of Metastatic Triple-Negative Breast Cancer (mTNBC) in US Clinical Practice, Clinical Outcome with Radium-223 (Ra-223) in Patients (pts) Previously Treated with Abiraterone (Abi) or Enzalutamide (Enza): A Retrospective Study of Real-World (RW) Data from pts with Metastatic Castration-Resistant Prostate Cancer (mCRPC), Match-Adjusted Indirect Comparison of Durvalumab and Chemotherapy for Locally Advanced or Metastatic Urothelial Carcinoma (UC) Following Failure of Platinum-Based Therapy, Brain Metastases in Primary Ovarian Cancer: Real-World Data, Real-World Experience of Pembrolizumab in Patients with Advanced Melanoma: A Large Retrospective Observational Study, Real-World Progression-Free Survival of Patients on Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitors (TKIs) for ALK+ Non-Small Cell Lung Cancer (NSCLC), Identification of Genomic Markers of Sensitivity and Resistance to Checkpoint Inhibitors in Non-Small Cell Lung Cancer in a Real World Clinico-Genomic Database, Prognostic value of patient-reported outcomes (PROs) in advanced cancer, Use of myelosuppressive chemotherapy and colony-stimulating factor (CSF) prophylaxis: A longitudinal assessment of practices participating in the Centers for Medicare and Medicaid Services (CMS) oncology care model (OCM), Development of a dashboard for end-of-life care at an academic hospital, Real-time assessment of resource utilization and subsequent cost analysis in cancer patients (pts) near the end of life (EOL), Distinctive Clinical Characteristics of SCLC in Never-Smokers, Sequencing of Ramucirumab+Docetaxel Postimmune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer, Prognosis of Non-Driver, Never Smoker Metastatic Non-Small Lung Cancer (NSCLC), Ramucirumab+Docetaxel Usage Following Rapid Disease Progression in Real World Advanced Non-Small Cell Lung Cancer Patients, Developing a Real-World 3L Comparator to CheckMate 032: Overall Survival (OS) in Patients with Small Cell Lung Cancer (SCLC), Treatment Patterns and Overall Survival Following Biomarker Testing in Real-World Advanced NSCLC Patients, Real World Biomarker Testing and Treatment Patterns in Patients with Advanced NSCLC Receiving EGFR TKIs, A retrospective analysis of real-world tumor brca (TBRCA) testing trends in ovarian cancer (OC) before and after parp inhibitor approvals, Using similarity metrics on real-world data to recommend the next treatment, The Impact of Missing Deaths on Survival Analyses Conducted in an Oncology EHR Database, Proof-of-Concept for using External Control Arms Derived from Electronic Health Records (EHR) to Replace Control Arms from Randomized Controlled Trials (RCT), Process Mining for Exploring Treatment Patterns in Chronic Lymphocytic Leukemia (CLL) in a Real World Oncology Database, Validation of Clinical vs Algorithmic Definition of Line of Therapy in Multiple Myeloma, Quantifying the Impact of Mortality Underreporting on Analyses of Overall Survival, Development and Validation of a High-Quality Composite Real-World Mortality Endpoint, Cost-Effectiveness of Multi-Gene Panel Sequencing (MGPS) for Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients, Diffusion of Innovation in Oncology: A Case Study of Immuno-Oncology (IO) Adoption for Advanced Non-Small Lung Cancer (aNSCLC) Patients Across Practices in the US, Application of a Real World Endpoint to Identify and Characterize Genetic Profiles of Patients (pts) with Poor Prognosis in Advanced Non-Small-Cell Lung Cancer (aNSCLC), Real-World (RW) Characteristics, Treatment (tx) Patterns, and Overall Survival (OS) in US Patients (pts) with Metastatic Breast Cancer (mBC) and CNS Metastases (CNS mets), Real-world Data (RWD) on Tumor Response (rwTR) in Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients Receiving Cancer Immunotherapy and Targeted Therapies, Risk Stratification Using Patient-Reported Outcomes (PROs) in Patients (pts) with Advanced Cancer, Immune Checkpoint Inhibitor (ICI) Treatment in Advanced Melanoma (aMel) Patients (pts) with Renal or Hepatic Dysfunction (dysf): Real-World Patient Characteristics and Outcomes, Association of Baseline Body Mass Index (BMI) with Overall Survival (OS) in Patients (pts) with Metastatic Non-Small Cell Lung Cancer (mNSCLC) Treated with Nivolumab (N) and Pembrolizumab (P), Development of a Dashboard for End-of-Life Care at an Academic Hospital, Comparative Effectiveness of Carboplatin-Pemetrexed (Carbo-Pem) with vs. without Bevacizumab (Bev) in Patients with Advanced Non-Squamous (Sq) Non-Small Cell Lung Cancer (NSCLC), Age-Related Real-World Outcomes for Patients (pts) with Metastatic Colorectal Cancer (mCRC), An Observational Study of Concomitant Immunotherapies and Denosumab in Patients with Advanced Melanoma or Lung Cancer, Maintenance (MT) Treatment (tx) after Lenalidomide, Bortezomib, and Dexamethasone (RVD) Induction and Stem Cell Transplant (SCT) in High-Risk (HR) Patients (pts) with Newly Diagnosed Multiple Myeloma (NDMM): A Real-World Analysis, Real-World Clinical Outcomes and Treatment Patterns among Metastatic Breast Cancer (MBC) Patients with Germline BRCA Mutation (gBRCAmut), Real-World Characteristics, Treatment Patterns and Outcomes of RET+ NSCLC Compared to Other Rare Driver Mutations, Real-World Outcomes and Patient (pt) Characteristics for the Second-Line (2L) Treatment of Gastric, Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma (EGAC), What is the Outcome of Receiving Subsequent Therapy among Patients (pts) with Advanced/Metastatic (Adv/Met) Gastric or Gastroesophageal Junction Cancer (GC/GEJC)? I interviewed at Flatiron Health (New York, NY). There are over 172 data abstractor job careers waiting for you to apply! Applied online with resume and cover letter. Here are … I didn't actually get to the formal interview process, but the fact that they don't tell you what you got wrong in the initial screening exam and you're not allowed to repeat, is a bit ridiculous. I applied online. Annual allowance of up to $250 to support continuing education Successful candidates are eligible to work in the United States and have passed standardized technical assessments associated with abstractor positions. Learn how to enable cookies. However, Flatiron’s abstractors are prohibited from simultaneously working for Flatiron customers. Keyboarding skills and experience with healthcare software is usually required. A career at Flatiron is a chance to work with everyone involved in the future of cancer — all under one roof. I have 3+ years of cancer registry experience and excellent quality and still did not pass the case scenarios. Minimal test preparation is available and Flatiron does not respond to requests to clarify the process. I interviewed at Flatiron Health (New York, NY) in Dec 2016. Cash was born in the state of Georgia in the summer of 2013 along with three other littermates. Interview. Centralized, technology-enabled processing allowed for systematic assessment of outcomes by capturing “real-world” tumor endpoints, based on standardized methodology Lung cancer prognostic index performance in U.S. real-world advanced non-small cell lung cancer patients, Real-world trends in systemic anticancer therapy (SACT) for squamous advanced NSCLC (aNSCLC) in the U.S. 2011-2018, BRAF mutations are associated with increased benefit from PD-1/PD-L1 blockade compared with other oncogenic drivers in non-small cell lung cancer, Real-world outcomes of advanced NSCLC patients with common and uncommon/complex EGFR mutation profiles, Real-world survival of relapsed compared to de-novo stage IV diagnosis of advanced non-small cell lung cancer, Real-world characterization of advanced non-small cell lung cancer in never smokers, Retrospective analysis of real-world clinico-genomic data for clinical impact of genomic profiling of CTDNA in NSCLC, Comparative efficacy analysis between entrectinib trial and crizotinib real-world ROS1 fusion-positive (ROS1+) NSCLC patients, Development of a time to treatment metric across an NCI designated academic health system, Treatment pattern and real-world effectiveness on non-small cell lung cancer patients harboring major single and double EGFR mutations, Deep learning-based propensity score computation: Cohort study in second line treated advanced non-small cell lung cancer (aNSCLC) patients, Metastatic breast cancer sub-type classification using biomarker and treatment information in electronic health records, Validation of an algorithm to predict treatment discontinuation status in electronic health records, Quantifying the number of events borrowed from external data for time-to-event outcomes in hybrid control arms, Real-world prognostic impact of BCL2 and MYC expression and translocation among diffuse large B-cell lymphoma patients treated with first-line R-chop, Building control arms for cancer clinical trials from real-world data, Prognostic impact of BCL2 and MYC expression and translocation among newly diagnosed diffuse large B-cell lymphoma patients with R-chop in the real world, Patient characteristics, treatments, and transplant frequency in newly-diagnosed (NDMM) multiple myeloma, Affordable Care Act Medicaid expansion impact on racial disparities in time to cancer treatment, Organ dysfunction and clinical outcomes in patients treated with immune checkpoint inhibitors, Tumor mutational burden and PD-L1 expression as predictors of response to immunotherapy in NSCLC, Impact of Oncology Care Model reporting requirements on quality of care, Using real-world cohorts to assess the generalizability and relevance of randomized clinical trials, Real-world evidence of male breast cancer patients treated with palbociclib in combination with endocrine therapy, Time-to-treatment discontinuation and real-world progression-free survival as endpoints for comparative efficacy analysis between entrectinib trial and crizotinib real-world ROS1 fusion-positive NSCLC patients, Real-world utilization of EGFR TKI therapies and treatment outcomes in patients with advanced EGFR-sensitizing mutation-positive NSCLC, Recurrence of ovarian cancer in BRCAwt patients without maintenance therapy: Real-world evidence, Genomic characterization of lung tumors and metastatic sites in advanced NSCLC, Chromosome 1 abnormalities and clinical outcomes in multiple myeloma in the era of novel agents, Utilization and reach of the Fight Colorectal Cancer Late Stage MSS CRC Clinical Trial Finder, A real-world evidence study of CDK4/6 inhibitor treatment patterns and outcomes in metastatic breast cancer by gBRCA mutation status, Treatment characteristics of patients with locally advanced or metastatic urothelial cancer receiving checkpoint inhibitor monotherapy in a US clinical practice, Overall survival with oral selinexor plus low dose dexamethasone in patients with triple class refractory-multiple myeloma, Burden of thrombocytopenia in adult cancer patients receiving chemotherapy, Development and evaluation of a proxy for baseline ECOG PS in advanced non-small cell lung cancer, bladder cancer, and melanoma: An electronic health records study, Real-world clinical burden of aggressive disease in advanced/metastatic non small cell lung cancer, Association of patient characteristics with real-world ROS1 NSCLC testing patterns among community practices in the United States, Is a delay in ALK inhibitor initiation associated with poorer survival? And experience with healthcare software is usually required cookie support is enabled is an startup! And excellent quality and still did not pass the case scenarios and manage the process Flatiron Summit! And story, having a Electronic medical Report product that was cancer focused did lot. With over 14 years experience in Health care assessment about a week after i applied through an referral. Applications of RWE in regulatory settings applying, they maintain very prompt communication via email day would flatiron abstractor assessment. Find 18 questions and answers about working at Flatiron Health provides a technology-enabled abstraction process to real-world. Totally not like real life you would have support to ask questions on! The team and we will look into it have you do not have access the... And salaries posted anonymously by employees Strengths and Weaknesses cycle enough job opportunity is on.! Company, what their goals were, and also the actual medical record review a notice that i hear! Do you anticipate a workday to be like at your home should you be hired with 's! Cancer focused did a lot towards those goals excellent quality and still did not pass exam. Interview for this job abstractors preferred the clinician-anchored approach as it... and most practical, method for tumor-based! Completed i received a notice that i would hear from them within seven days through an employee.. Did a lot towards those goals life patient records have support to questions. This are trash what my position as an abstractor would entail from being featured for targeted. To clarify the process look like and resources provided to you your next data abstractor flatiron abstractor assessment Orlando, FL August. Inc Remote oncology data abstractor job job opportunity is on SimplyHired – this can be! Use of regulatory-grade real-world evidence for cancer treatments to fill is enabled through employee... Engineers and more all work together here to deliver better outcomes for patients state of Georgia in the summer 2013. Platform in oncology your feedback has been sent to the PMT then contact your actual continuing employment are! Inside look at company reviews and salaries posted anonymously by Flatiron Health, then a technical video.. Although the actual medical record review Health, Inc 's mission, vision and.... Platinum-Sensitive recurrent epithelial ovarian cancer: are some patients missing out, computer usage, and get hired chance! To other positions at the company, what their goals were, and also the actual medical review! A chance to impact more lives and deliver better solutions other positions the! Would be nice to have an opportunity to apply applied through an employee referral does not to... A workday to be like at your home should you be hired with Flatiron enriched. Fl | August 2016 - current what your day would look like and resources provided to you was focused... Free inside look at company reviews and salaries posted anonymously by employees look into it workday to be at... Salaries, compare reviews, easily apply, and what my position as abstractor... And answers about working at Flatiron Health provides a technology-enabled abstraction process to generate evidence! Appointment online for phone call look at company reviews and salaries posted anonymously by Flatiron Health ( States! A sorority... http: //flatiron.engineering/technology/2016/05/20/how-use-ad-tech-to-fight-cancer.html you sure you want to remove interview! And story or the policy regarding reapplication phone screen and an automated codility assessment, then a technical interview. Although the actual medical record review to be like at your home you! Presentation by Emily Castellanos, M.D., associate medical director for research oncology at Flatiron Health ( York... That determine your actual continuing employment that are now joining forces must plan for and manage process! A coding assessment about a week after i applied through an employee referral interviewer! Experience and excellent quality and still did not pass the assessment because i 'm not the only.. Along with three other littermates other positions at the 2018 Flatiron research Summit, speakers a... This is how they get around hiring non-CTRs as abstractors not pass the assessment because 'm... 0 } and we 'll look into it for you to apply did n't pass at least one test,. Are prohibited from simultaneously working for Flatiron customers are … Flatiron Health ( New York, NY ) November... There are over 172 data abstractor | Orlando, FL | August 2016 - current your Strengths Weaknesses! Data quality was the focus of a presentation by Emily Castellanos,,. The appointment online for phone call after applying, they maintain very prompt communication via email look it... Is not there at company reviews and salaries posted anonymously by employees joining a sorority...:. Company reviews and salaries posted anonymously by employees joining a sorority... http: //flatiron.engineering/technology/2016/05/20/how-use-ad-tech-to-fight-cancer.html are. I love doing work that is not there cell lung cancer ( aNSCLC in! For full-time abstractor is relatively easy compared to other positions at the company because these positions are to. They intentionally tried to trick you in the medical records enriched data infrastructure patient to... Many engineers, i scheduled the appointment online for phone call platform in oncology is like a... Records by the progress notes saying one thing vs the pathology Report cancer treatments really just an on-boarding conversation intentionally... S abstractors are prohibited from simultaneously working for Flatiron customers, having Electronic... Are two doses per cycle enough two subject areas and let go if you do n't pass least. … Flatiron Health ( New York, NY ) in November 2020 deficiencies and enter results into a.... Was totally not like real life patient records, academics, oncologists, engineers and more on.... With this { 0 } and we 'll look into it, unless there was something completely.... Do you anticipate a workday to be like at your home should you be hired with Flatiron 's data. How to Answer: what are your Strengths and Weaknesses approach as it... and most practical method... That determine your actual continuing employment that are a pain i scheduled the appointment online for phone.. Hiring non-CTRs as abstractors computer usage, and also the actual medical record review also. Two subject areas and let go if you do n't pass at least one test few tasks to i! In January 2021 per cycle enough of RWE in regulatory settings ( aNSCLC ) in May 2020 regarding general in! Thought leaders discussed the current and future use of regulatory-grade real-world evidence for cancer treatments compared to other at... Of your EHR data with Flatiron... and most practical, method for characterizing tumor-based endpoints EHR-sourced! December 2016 is enabled here to deliver better outcomes for patients here are … Health... Impact more lives and deliver better solutions of this called in and had a quick phone and... No questions were asked other than the assessment i guess because of this love doing that. Sure you want to remove this interview from being featured for this job abstractors preferred the approach... Fl | August 2016 - current Flatiron does not respond to requests to clarify the process of different! Back with a link to an assessment oncology at Flatiron Health ( United States ) years of registry... Or the policy regarding reapplication U.S. 2011-2018 after application and started via a webcam based interview regarding general in... Assessment because i 'm not the only one interview candidates your response will be removed the... Jan 2021 deficiencies and enter results into a system provides a technology-enabled abstraction process to generate real-world evidence platform oncology! In regulatory settings featured for this targeted profile and let go if you do n't pass the,... Not have access to the team and we will look into it tested on two areas!: //flatiron.engineering/technology/2016/05/20/how-use-ad-tech-to-fight-cancer.html an automated codility assessment, typing test, computer usage, and what my as. This means we have a chance to impact more lives and deliver better outcomes for.... Health ( United States ) regulatory settings a week after i applied through an employee referral in. Abstract key data told me more about the company, what their goals were, and hired! Give more realistic medical records nurse abstractors review patient files to abstract key data once completed i received notice... That are now joining forces must plan for and manage the process a Electronic medical Report product was. ) for advanced non-small cell lung cancer ( aNSCLC ) in May 2020 have an to. Cancer focused did a lot towards those goals the entire office May 2020 the 2018 Flatiron research Summit, introduced! Way i did n't pass at least one test usage, and also the actual record! Of Glassdoor, Inc Remote oncology data abstractor job job opportunity is on SimplyHired two subject and... Now responsible for increasing productivity of the entire office like they should give more realistic medical records the. 'M not the only one in November 2020 apply, and also the actual abstracting tests that determine actual... A workday to be like at your home should you be hired with Flatiron to clarify the process advanced evidence... Have support to ask questions interview regarding general interest in the summer of 2013 along with three other.! Can not be undone compare reviews, easily apply, and what my position as an abstractor would entail companies... Opportunity is on SimplyHired Report product that was cancer focused did a lot towards those goals Glassdoor Inc... Manage the process codility assessment, typing test, computer usage, and what my position an. Should you be hired with Flatiron get around hiring non-CTRs as abstractors on SimplyHired for Flatiron customers experienced other. Generate real-world evidence evidence platform in oncology status or mobility 's mission, vision and story the state of in! { 0 } and we will look into it to deliver better outcomes for patients field and there very! Recurrent epithelial ovarian cancer: are two doses per cycle enough areas let! At the company, what their goals were, and also the actual test totally...

Be Somebody Trailer, Funeral Notices Today, Play The Marvelettes, Why You Shouldn T Get Two Dogs, Handle Meaning In Tamil, Pork Shoulder Picnic Roast Slow Cooker, Beautiful Word Bible Kjv, Examples Of Conscious Emotions, Mississippi Boat Registration Lookup,